Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM.
Martin M, et al.
Breast Cancer Res Treat. 2011 Jul;128(1):127-36. doi: 10.1007/s10549-011-1461-y. Epub 2011 Apr 5.
Breast Cancer Res Treat. 2011.
PMID: 21465170
Clinical Trial.